Search clinical trials for: vernakalant hydrochloride

Total 7363 results

Advanz Pharma

Completed

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Atrial Fibrillation
Advanz Pharma
Astellas Pharma US, Inc.

Completed

A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter (Scene 2)

Atrial Flutter

United States, Canada, Denmark, Sweden
Advanz Pharma
Astellas Pharma US, Inc.

Completed

Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation (ACT I)

Atrial Fibrillation

United States, Canada, Sweden, Denmark
Astellas Pharma Inc
Advanz Pharma

Completed

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Atrial Fibrillation | Atrial Flutter

United States, Argentina, Canada, Chile, Denmark, Mexico, Sweden
Correvio International Sarl

Completed

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Atrial Fibrillation

Denmark, Spain, Austria, Finland, Germany, Sweden
Advanz Pharma

Terminated

A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045) (ACT V)

Atrial Fibrillation
Astellas Pharma Inc
Advanz Pharma

Completed

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation (ACT 4)

Atrial Fibrillation

United States, South Africa, Canada, Argentina, Denmark, Sweden
Advanz Pharma

Completed

Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

Atrial Fibrillation

Spain, Netherlands, New Zealand, Australia, Sweden, Denmark, Slovakia, Belgium, Estonia, Serbia, Russian Federation, Czech Republic, Bulgaria, Germany, Portugal, Croatia, Switzerland, Hungary, Lithuania, Poland, Romania, Singapore, South... and more
Advanz Pharma

Completed

Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

Atrial Fibrillation

Netherlands, United States, Canada, Denmark
Medical University of Vienna

Completed

Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

Atrial Fibrillation

Austria
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis

Tinea Corporis

Dominican Republic, Honduras
Ottawa Hospital Research Institute

Recruiting

RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

Atrial Fibrillation

Canada
David Filgueiras-Rama
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Completed

Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents (SELECTCARFAP)

Paroxysmal Atrial Fibrillation

Spain
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Maastricht University Medical Center

Unknown

Vernakalant Versus Flecainide: Atrial Contractility

Atrial Fibrillation

Netherlands
Neelesh Sharma MD PhD

Completed

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Xijing Hospital of Digestive Diseases

Completed

Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

Colorectal Adenomas

China
Xijing Hospital of Digestive Diseases

Completed

A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer

Colorectal Adenomas

China
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet

Uremic Pruritus

China
Galderma R&D

Completed

Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
M.D. Anderson Cancer Center

Withdrawn

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8
Betta Pharmaceuticals Co., Ltd.
Tigermed Consulting Co., Ltd

Completed

Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Psoriasis

China
Epygenix

Completed

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

Dravet Syndrome

United States
Janssen Research & Development, LLC

Completed

An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride

Sexual Dysfunction, Physiological | Ejaculation

Germany, Spain, Portugal, Finland, Sweden, Austria
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal Large B-Cell Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

United States
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
WPD Pharmaceuticals Sp. z o.o.
Worldwide Clinical Trials

Not yet recruiting

A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas

High Grade Glioma
PhytoHealth Corporation

Completed

Bioavailability, Pharmacokinetics and Safety Evaluation of Phencynonate Hydrochloride in Healthy Volunteers

Healthy

Taiwan
Zhejiang University
Huashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Terminated

A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

Hepatocellular Carcinoma

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
National Institute of Allergy and Infectious Diseases...
International Tuberculosis Research Center

Withdrawn

Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs

Refractory Pulmonary Tuberculosis

Korea, Republic of
Mundipharma K.K.

Completed

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Recurrent or Refractory T/NK-cell Malignancies

Japan
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

GW786034 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
BioCryst Pharmaceuticals

Completed

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Yansong Lin

Active, not recruiting

Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib

DTC - Differentiated Thyroid Cancer

China
University of Maryland, Baltimore

Suspended

Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride

Aortic Aneurysm, Thoracic

United States
Yizhuo Zhang

Unknown

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Sarcoma
Mundipharma K.K.

Completed

Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

Recurrent or Refractory PTCL

Japan
GlaxoSmithKline

Completed

Post Marketing Surveillance for Contac Bien Z in Japan

Allergic Rhinitis | Seasonal Allergic Rhinitis

Japan
Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

Non-small Cell Lung Cancer

China
AVEO Pharmaceuticals, Inc.

Completed

A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Institute of Cancer Research, United Kingdom
National Cancer Institute (NCI)

Unknown

17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
BioCryst Pharmaceuticals

Completed

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

Lymphoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
SK Chemicals Co., Ltd.
Toray Industries, Inc

Completed

Safety Study of TRK-820 for Patient With Hemodialysis (TRK-820)

Chronic Renal Failure

Korea, Republic of
IntraBiotics Pharmaceuticals

Terminated

Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia

Pneumonia

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma

Anlotinib | Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound Complications

China
WPD Pharmaceuticals Sp. z o.o.
National Center for Research and Development, Poland; Worldwide Clinical Trials

Recruiting

Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

Recurrent Glioblastoma Multiforme

Poland

Search clinical trials for: vernakalant hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations